Physician profile
Uma Srivastava
NPI 1194815290
$23,040.27
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $7,329 · 2021: $5,175.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21,996.66 | 2019-2021 | |
| Alkermes, INC. | $449.95 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $173.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $159.47 | 2019-2021 | |
| Acorda Therapeutics, INC | $69.77 | 2021 | |
| Adamas Pharmaceuticals, INC. | $35.03 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $22.07 | 2019 | |
| Allergan, INC. | $20.99 | 2019 | |
| Biogen, INC. | $20.87 | 2019 | |
| Amneal Pharmaceuticals LLC | $18.58 | 2021 | |
| Lundbeck LLC | $17.59 | 2019 | |
| Acadia Pharmaceuticals INC | $15.89 | 2019 | |
| Bausch Health US, LLC | $15.70 | 2021 | |
| Lilly USA, LLC | $12.09 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.